Last $3.15 USD
Change Today +0.06 / 1.94%
Volume 2.5M
CPRX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/15/14 All times are local (Market data is delayed by at least 15 minutes).

catalyst pharmaceutical part (CPRX) Snapshot

Open
$3.26
Previous Close
$3.09
Day High
$3.36
Day Low
$3.12
52 Week High
10/3/13 - $3.65
52 Week Low
11/14/13 - $1.29
Market Cap
211.6M
Average Volume 10 Days
1.4M
EPS TTM
$-0.26
Shares Outstanding
67.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CATALYST PHARMACEUTICAL PART (CPRX)

Related News

No related news articles were found.

catalyst pharmaceutical part (CPRX) Related Businessweek News

No Related Businessweek News Found

catalyst pharmaceutical part (CPRX) Details

Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. The company focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. Its principal product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. The company also develops CPP-115, a vigabatrin analog to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, such as post-traumatic stress disorder and Tourette syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.

7 Employees
Last Reported Date: 03/19/14
Founded in 2002

catalyst pharmaceutical part (CPRX) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $426.5K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $231.0K
Chief Operating Officer and Chief Scientific ...
Total Annual Compensation: $309.4K
Compensation as of Fiscal Year 2013.

catalyst pharmaceutical part (CPRX) Key Developments

Catalyst Pharmaceutical Partners, Inc. Appoints David D. Muth as Executive Vice President, Corporate Development

Catalyst Pharmaceutical Partners Inc. announced the appointment of David D. Muth to the newly created position, Executive Vice President, Corporate Development. Mr. Muth will report to Patrick McEnany, Chairman, President and Chief Executive Officer of Catalyst. As Executive Vice President, Corporate Development, Mr. Muth will be responsible for all of Catalyst's corporate development activities and will work closely with the other members of the Catalyst team in preparing a commercialization strategy for Firdapse. Mr. Muth most recently served, from 2010 to 2014, as the President and CEO of Croma Pharmaceuticals Inc., where he established North American operations, gained approval of and launched 10 Ocular Surgical products, while building a Canadian Ophthalmology sales organization.

Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115

Catalyst Pharmaceutical Partners Inc. announced the initiation of its second Phase 1 safety and tolerance study for CPP-115, a novel GABA aminotransferase (GABA-AT) inhibitor. The Phase 1(b) trial is designed in 2 parts to evaluate the safety and tolerability of single and multiple doses of CPP-115, including CNS side effects, and respiratory and cardiovascular safety. In addition: Part 1 of the trial is an open label, single descending dose study in up to 3 cohorts of 2 normal healthy, male volunteers, intended to verify that the drug crosses the blood-brain barrier at levels sufficient to significantly raise brain GABA levels as measured by Magnetic Resonance Spectroscopy (MRS). Catalyst believes increases in brain GABA, an inhibitory neurotransmitter, to be a biomarker for the potential efficacy of CPP-115 as a treatment for Tourette Syndrome, Post-Traumatic Stress Disorder (PTSD) and infantile spasms. If the first dose shows a significant increase, lower single doses will be evaluated to determine a minimal effective dose to be able to set the doses to be evaluated in the multiple dose part of the trial. Part 2 of the study is designed as a randomized, double-blind, multiple ascending dose study in 4 cohorts of eight normal healthy, male volunteers. In addition to studying basic human safety and tolerability, the effect of multiple doses of CPP-115 on brain GABA levels will also be followed by MRS.

Catalyst Pharmaceutical Partners Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Catalyst Pharmaceutical Partners Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported a GAAP net loss of $3,198,020, or $0.05 per basic and diluted share, compared to a GAAP net loss of $3,143,590, or $0.01 per basic and diluted share, for the same period in 2013. Excluding non-cash expense of $223,591 attributable to the change in fair value of liability-classified warrants, Non-GAAP net loss was $2,974,429 or $0.05 per share for the second quarter of 2014. In comparison, Non-GAAP net loss for the second quarter of 2013 was $2,645,003, or $0.06 per share, which excludes non-cash expense of $498,587 attributable to the change in fair value of liability-classified warrants. Loss from operations was $2,990,173 against $2,653,529 for the same period a year ago. Loss before income taxes was $3,198,020 against $3,143,590 for the same period a year ago. For the six months, the company reported GAAP net loss of $7,009,139, or $0.12 per basic and diluted share, compared to a GAAP net loss of $4,887,879, or $0.12 per basic and diluted share, for the same period in 2013. Excluding non-cash expense of $559,105 attributable to the change in fair value of liability-classified warrants, Non-GAAP net loss was $6,450,034 or $0.11 per share for the six months ended June 30, 2014. In comparison, Non-GAAP net loss for the six months ended June 30, 2013 was $4,343,966, or $0.11 per share, which excludes non-cash expense of $543,913 attributable to the change in fair value of liability-classified warrants. Loss from operations was $6,498,538 against $4,358,959 for the same period a year ago. Loss before income taxes was $7,009,139 against $4,887,879 for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPRX:US $3.15 USD +0.06

CPRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CPRX.
View Industry Companies
 

Industry Analysis

CPRX

Industry Average

Valuation CPRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CATALYST PHARMACEUTICAL PART, please visit www.catalystpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.